DUR-928

DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis

March 21, 2019

https://www.biospace.com/article/releases/durect-announces-patient-dosing-in-phase-2a-proof-of-concept-clinical-trial-of-topical-dur-928-in-patients-with-mild-to-moderate-plaque-psoriasis/

http://investors.durect.com/phoenix.zhtml?c=121590&p=irol-newsArticle&ID=2391958

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

March 13, 2019

https://clinicaltrials.gov/ct2/show/NCT03837743?type=Intr&cond=Psoriasis&lupd_s=02%2F27%2F2019&lupd_d=14

Condition : Plaque Psoriasis

Interventions : Drug: DUR-928 Topical Solution; Drug: Vehicle Topical Solution

Sponsors : Therapeutics, Inc.; Durect

Recruiting

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

NCT03837743

Tue, 12 Feb 2019 12:00:00 EST

Last Update Posted: 03/13/19 10:17AM